Get started
REGENERON PHDRNREGENERON PHDRNREGENERON PHDRN

REGENERON PHDRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

REGN34 chart


Full chart

Key facts today


Goldman Sachs has lowered its price target for Regeneron Pharmaceuticals (REGN) from $1019.00 to $917.00 per share.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪356.18 B‬ BRL
Dividend yield (indicated)
0.10%
Price to earnings Ratio (TTM)
16,176.47
Basic EPS (TTM)
0.00 BRL
Net income (FY)
‪23.79 B‬ BRL
Revenue (FY)
‪76.56 B‬ BRL
Shares float
—
Beta (1Y)
−0.30

About Regeneron Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Leonard S. Schleifer
Website
regeneron.com
Headquarters
Tarrytown
Founded
1988
ISIN
BRREGNBDR005
FIGI
BBG00P14K7Y9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

REGN34 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

REGN34 highest yielding bonds


REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050
Yield to maturity
8.09%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030
Yield to maturity
5.59%
Maturity date
Sep 15, 2030

See all REGN34 bonds 

Sparks


Curated watchlists where REGN34 is featured.

See all sparks 


Check out other big names from the same industry as REGN34.